Table 4.
cAMP and cGMP phosphodiesterase inhibitor for COPD.
| S. no. | Inhibitor/drug | Mechanism/effect | Clinical progress | References |
|---|---|---|---|---|
| 1 | Roflumilast | PDE4 inhibitor | US-FDA approved drug | [177, 178] |
|
| ||||
| 2 | GSK-256066 | PDE4 inhibitor | 4 Weeks inhaled treatment (NCT00549679) |
[179] |
|
| ||||
| 3 | CHF6001 | PDE4 inhibitor | Clinical testing going on (NCT01730404) | [180] |
|
| ||||
| 4 | Tadalafil | PDE5 inhibitor | Approved for pulmonary arterial hypertension 12-week treatment (NCT01197469) | [181] |
|
| ||||
| 5 | RPL554 | PDE3/PDE4 inhibitor | Being investigated as an adjunct (NCT02542254) |
[182] |